Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming

Abstract

A method of immunizing against plaque forming diseases using display technology is provided. The method utilize novel agents, or pharmaceutical compositions for vaccination against plaque forming diseases which rely upon presentation of an antigen or epitope on a display vehicle. The method further includes agents, or pharmaceutical compositions for vaccination against plaque forming diseases, which rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, disaggregation of plaques results from the immunization.

What is claimed is:  
     
         1 . A method for inhibiting aggregation of β-amyloid in a subject or disaggregating aggregated β-amyloid in a subject comprising administering to a subject in need thereof an effective amount of a filamentous bacteriophage which displays an antibody or epitope binding fragment thereof which binds to said β-amyloid so as to inhibit aggregation of said β-amyloid in said subject and/or to cause disaggregation of said β-amyloid aggregate in said subject.  
     
     
         2 . The method of  claim 1 , wherein said bacteriophage displays an antibody or epitope binding fragment which binds to SEQ ID NO: 1.  
     
     
         3 . The method of  claim 2 , wherein said bacteriophage displays an antibody or epitope binding fragment which binds to SEQ ID NO: 1 in a peptide comprising SEQ ID NO: 1.  
     
     
         4 . The method of  claim 3 , wherein said peptide is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 21, and SEQ ID NO: 22.  
     
     
         5 . The method of  claim 1 , wherein said antibody or epitope binding fragment thereof is displayed via coat glycoprotein VIII on said bacteriophage.  
     
     
         6 . A method for inhibiting aggregation of a prion protein in a subject or disaggregating aggregated prion protein in a subject comprising administering to a subject in need thereof an effective amount of a filamentous bacteriophage which displays an antibody or epitope binding fragment thereof which binds to said prion protein so as to inhibit aggregation of said prion protein in said subject and/or to cause disaggregation of said prion protein aggregate in said subject.  
     
     
         7 . The method of  claim 6 , wherein said prion protein is scrapie isoform (PrP sc ).  
     
     
         8 . The method of  claim 7 , wherein said antibody or fragment binds to SEQ ID NO: 26.  
     
     
         9 . The method of  claim 8 , wherein said antibody or fragment binds to SEQ ID NO: 26 in a peptide comprising SEQ ID NO: 26.  
     
     
         10 . The method of  claim 9 , wherein said peptide is SEQ ID NO: 25.  
     
     
         11 . The method of  claim 6 , wherein said antibody or epitope binding fragment thereof is displayed via coat glycoprotein VIII on said bacteriophage.  
     
     
         12 . the method of  claim 6 , wherein said antibody is selected from the group consisting of mAb 3-11 and mAb 2-40.  
     
     
         13 . An antibody or epitope binding fragment thereof which binds to a prion protein so as to inhibit aggregation of said prion protein and/or to cause disaggregation of said prion protein aggregate.  
     
     
         14 . The antibody or epitope binding fragment thereof of  claim 13 , wherein said prion protein is scrapie isoform (PrP sc ).  
     
     
         15 . The antibody or epitope binding fragment thereof of  claim 14 , wherein said antibody or epitope binding fragment binds to SEQ ID NO: 26.  
     
     
         16 . The antibody or epitope binding fragment thereof of  claim 15 , wherein said antibody or epitope binding fragment binds to SEQ ID NO: 26 in a peptide comprising SEQ ID NO: 26.  
     
     
         17 . The antibody or epitope binding fragment thereof of  claim 16 , wherein said peptide is SEQ ID NO: 25.  
     
     
         18 . The antibody of  claim 13 , which is selected from the group consisting of mAb 3-11 and mAb 2-40.  
     
     
         19 . A pharmaceutical composition in unit dosage form, comprising a pharmaceutically acceptable carrier and, as active ingredient, a filamentous bacteriophage displaying an antibody or epitope binding fragment thereof which binds to β-amyloid so as to inhibit aggregation of said β-amyloid in a subject and/or to cause disaggregation of any β-amyloid aggregate in the subject.  
     
     
         20 . The pharmaceutical composition of  claim 19 , wherein said bacteriophage displays an antibody or epitope binding fragment which binds to SEQ ID NO: 1.  
     
     
         21 . The pharmaceutical composition of  claim 20 , wherein said antibody or epitope binding fragment is displayed via coat glycoprotein VII on said bacteriophage.